H.I.G. BioVentures

H.I.G. BioVentures is the life science investment affiliate of H.I.G. Capital and has offices across the USA. H.I.G. BioVentures has assets under management of $4m and is investing from its second fund which closed at $268m in 212. The firm typically makes initial equity investments of $3-7m with the potential to invest up to $2m over the life of an investment. While most of H.I.G. BioVentures? portfolio companies are US-based the firm will consider opportunities worldwide.
Enoch Kariuki
Vice President 

Health Beacons United States

Health Beacons is an early stage medical device company that is revolutionizing the standard of care for marking and surgically removing non-palpable breast tumors. Physicians are actively seeking an alternative procedure and are enthusiastic about ours, which employs RFID markers that are read with handheld readers, because it addresses all the shortcomings of the current method.  We have a fully functional prototype that has been used successfully in almost 40 human cases and are working on our 510K submission. Investment to date has been from founders, friends and family.  We are currently seeking $1.5M in an equity round to support regulatory clearance, and will require another $2-3M for commercialization which is planned for Q1 2016.

Year Founded
2008
Main Sector
Medtech Phase of Development
Current Investors

Founders, friends and family

Nancy Confrey

HealthQuest Capital United States

Sofinnova Ventures was founded in 1974 and is based in Menlo Park, CA. The firm has approximately $1b of assets under management, and makes life science investments from two fund families; the main Sofinnova Ventures fund and Sofinnova HealthQuest Capital. Sofinnova Venture Partners IX closed at $500 million in 2014, and the debut HealthQuest fund closed at $110 million in 2014. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. Sofinnova Ventures plans to make 4-6 new investments in life science companies in 2014. 

The Sofinnova Ventures main fund invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-30m. The fund invests in companies based in North America or Europe. 

HealthQuest Capital invests in non-biopharmaceutical life science and medtech companies and typically makes initial investments of $2-3m, with the potential for total investments of $5-6m. HealthQuest Capital is a venture growth fund focused on commercial-stage technologies, and only invests in companies headquartered in North America (particularly the US Southeast or West Coast).

Garheng Kong
Garheng Kong
Managing Partner 
Randy Scott
Randy Scott
LinkedIn logo Partner 

Hercules Technology Growth Capital Inc.

Hercules Technology Growth Capital is a Private Equity company founded in 23 Headquartered in Palo Alto California with additional offices in Boston Boulder New York and McLean. The firm manages an evergreen structure and primarily provides high-growth companies in the life science space with senior secured debt financing. The firm can allocate up to $5 million per investment. The firm is very flexible with deal structures that can be customized to help companies reach their key milestones. The firm primarily invests in companies headquartered in the US but has the ability to invest overseas as well.
Janice Borque
Managing Director Life Sciences 

Horizon Technology Finance United States

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Year Founded
2003
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jerry Michaud

Hub Angels Investment Group

Hub Angels Investment Group is an angel group that was founded in 2 and is based in Cambridge Massachusetts. The firm manages a fund structure and recently closed its 4th fund making the total AUM of the group around $4 million. The firm makes investments ranging from $25 to $5 in equity for companies that are at least 12 months old. The firm makes investments ranging from four to eight years and prefers to invest in companies whose valuation does not exceed $1 million. Hub angels plans on making approximately 3 allocations over the next 6-9 months with stated interest in diagnostics and medical device companies.
Randy Barko
Member 

Immunova LLC United States

Immunova is a startup with  an IP portfolio licensed from Yale and the Johns Hopkins Universities.

Immunova's technology platform has a unique capability to deliver one or more drugs to the tumor/disease microenvironment. The drugs can be proteins, small molecules or nucleic acids. The delivery platfrom has demonstatable advantages over other delivery systems. The technology has applications in oncology and inflammation.

The company's lead asset is positioned in oncology. IMM-01, consists of two drugs that (a) undermine the tumor micorenvironment and (b) increase anti-tumor cell mediated immunity. This asset is capable of curing mice of metastatic disease. Further, it significantly enhances the activites of immune checkpoint inhibitors. It is non toxic.

The company is seeking investment and R&D partners. Immunova has defined the path to a Phase I/IIa multidose trial which could initiate within 15 months of funding. Immunova is also seeking partners who wish to validate this platform in oncology and inflammation.

Website:
www.immunova.net
Year Founded
2011
Biotech Subsector
Biotech Phase of Development
Technology Overview
Immunova’s platform enables effective drug combination therapy. Chemically diverse drugs such as biologics and small molecules can be formulated and encapsulated in a liposome and thereby delivered systemically to a target cell or environment where each encapsulated API can be released independently in a controlled or tuneable manner using our proprietary technology. Importantly, this approach also potentiates existing or novel therapies often increasing their therapeutic index. LipoGel-TR is a hybrid platform of liposomes and PLGA nanoparticle delivery systems designed to possess the positive features of each platform while minimizing the negative aspects. Many of the building blocks required to make a LipoGel can be bought preassembled and GMP from third party providers thus shortening development timelines. We have demonstrated the superiority of LipoGels in numerous in vitro assays (drug loading and release and potency) and animal models of disease (efficacy and survival). Using our technology we have demonstrated that we can (a) direct one or more drugs to the TME, (b) increase drug synergies, efficacy and potency of chemo and immunotherapies, (c) decrease drug toxicity, (d) increase immune cell activity and (e) generate new intellectual property.
Alliance & Collaborations
The company is actively seeking partners in oncology and inflammation.
Supporting Metrics or Evidence
The technology has been published in high profile journals and the founder actively collaborates with numerous scientists at leading institutions. The Company’s initial focus is cancer immunotherapy: delivery of molecules that modulate immunity, positively and negatively, in order to undermine the tumor microenvironment and allow the immune system to keep pace with tumor evolution and thus be primed to eradicate disease. Our lead asset, IMM01: • Is targeted to and accumulates in tumors; • Encapsulated APIs are slowly released over 7 days and this can be further modulated; • Dramatically increases potency and efficacy: in a murine model of metastatic disease, IV delivery of IMM-01 results in 85% survival of IMM-01-treated mice at day 60 whereas all untreated mice, as well as mice treated with the drugs in solution, have died by day 30; • Increases immune infiltrate within the tumor which correlates with good patient outcomes • Significantly increases the potency of anti-PD1 and anti-CTLA4 mAb therapy in a mouse model of metastatic disease supporting published MoA studies • Is not toxic; there are no signs of renal, hepatic, bronchial, RBC or leukocyte toxicity when IMM-01 is administered to mice at high doses.
Current Financing Needs
Immunova is seeking $8-10M to fund operations for three years and including a phase I/IIa clinical trial
Current Timeline
Pending financing, IMM-01 is ca 15 months from a Phase I/IIa clinical trial
Current Investors
Angel-backed to date
IP Status
The company has licensed 4 granted and 3 pending patents
Recent Milestones
Q3 2014 • Demonstration of synergy with checkpoint inhibitors • New patent filed • Patent granted • Academic founder noted as a bioentrepreneur to watch by Nature Biotechnology Q4 2014 • First phase technology transfer to CMO • Identified lead clinical trial site and PI • Determined drug needs for clinical trial • Regulator engaged for ‘preIND meeting’
Management Team Highlights
The Company has recruited an impressive team that has an established and successful record of building companies. The management, advisors and scientific founders have an established network of both pharmaceutical and medical contacts and extensive experience running biotechnology firms and executing clinical trials. For reference, the following biotech startups founded/managed/invested in by Immunova Management or Advisors, were acquired prior to FDA approval: • Neurovir Therapeutics, Inc. – Acquired by MediGene AG for $42M • Nurel Therapeutics – acquired by DyaMid AB (undisclosed) • Proximagen plc. – Acquired by Upsher Smith for $550M • PharmaGenics Inc. – acquired by Genzyme for $28M • Prostagen– acquired by Cytogen (undisclosed)
Brian Horsburgh

InterWest Partners

InterWest Partners founded in 1979 is a venture capital firm based in Menlo Park California. The firm?s primary focus is providing venture capital to early-stage healthcare and information technology companies. The firm has raised 1 funds to date with over $2.8 billion in committed capital. The firm?s tenth fund closed in 29 at $65 million. The firm generally invests in the Series A and B rounds, initially allocating $8-12 million and up to $2 million over the life of the investment. The firm primarily invests in US-based companies but will also selectively consider opportunities abroad. The firm is actively seeking new investment opportunities.
Doug Fisher
Partner 

Johnson & Johnson (Medical Devices)

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick NJ with an Innovation Center in Cambridge MA. The firm invests in a variety of fields within the life science sector including medical devices. J&J?s medical device investments are highly varied in both size and structure, the structure may involve milestone payments or may be an equity investment. J&J is interested in early stage medical device companies located globally.

Ibraheem Badejo
Senior Director New Ventures 

Johnson & Johnson Innovation United States

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick, NJ, with an Innovation Center in Cambridge, MA. The firm invests in a variety of fields within the life science sector, including medical devices. J&J’s medical device investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment. J&J is interested in early stage medical device companies located globally.

Thorsten Melcher
New Ventures